LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 54

Search options

  1. Article ; Online: Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.

    Johnston, Stephen R D / André, Valérie

    The Lancet. Oncology

    2022  Volume 24, Issue 3, Page(s) e104

    MeSH term(s) Humans ; Female ; Breast Neoplasms ; Aminopyridines ; Benzimidazoles ; Immunologic Factors
    Chemical Substances abemaciclib (60UAB198HK) ; Aminopyridines ; Benzimidazoles ; Immunologic Factors
    Language English
    Publishing date 2022-11-08
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(23)00065-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Dictionnaire des femmes des Lumières

    André, Valérie / Krief, Huguette

    (Dictionnaires références ; ...)

    2015  

    Author's details sous la dir. de Huguette Krief et Valérie André. Avec une introd. de Huguette Krief
    Series title Dictionnaires références
    ...
    Language French
    Publisher Champion
    Publishing place Paris
    Document type Book
    ISBN 9782745324870 ; 274532487X
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Book: Dictionnaire des femmes des Lumières

    André, Valérie / Krief, Huguette

    (Dictionnaires & références ; 25,[1])

    2015  

    Author's details sous la dir. de Huguette Krief et Valérie André; avec une introd. de Huguette Krief
    Series title Dictionnaires & références ; 25,[1]
    Language French
    Size 650 S.
    Publisher Champion
    Publishing place Paris
    Document type Book
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Book: Dictionnaire des femmes des Lumières

    André, Valérie / Krief, Huguette

    (Dictionnaires références ; 25,[2])

    2015  

    Author's details sous la dir. de Huguette Krief et Valérie André; avec une introd. de Huguette Krief
    Series title Dictionnaires références ; 25,[2]
    Language French
    Size S. 652 - 1337
    Publisher Champion
    Publishing place Paris
    Document type Book
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.

    Goetz, Matthew P / Cicin, Irfan / Testa, Laura / Tolaney, Sara M / Huober, Jens / Guarneri, Valentina / Johnston, Stephen R D / Martin, Miguel / Rastogi, Priya / Harbeck, Nadia / Shahir, Ashwin / Wei, Ran / André, Valérie / Rugo, Hope S / O'Shaughnessy, Joyce

    NPJ breast cancer

    2024  Volume 10, Issue 1, Page(s) 34

    Abstract: In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively ... ...

    Abstract In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively manage adverse events. Exploratory analyses to investigate the impact of dose reductions on efficacy were conducted. Across the three patient subgroups as defined by relative dose intensity (≤66%, 66-93%, ≥93%), the estimated 4-year IDFS rates were generally consistent (87.1%, 86.4%, and 83.7%, respectively). In the time-dependent Cox proportional hazard model, the effect of abemaciclib was consistent at the full dose compared to being reduced to a lower dose (IDFS hazard ratio: 0.905; 95% confidence interval: 0.727, 1.125; DRFS hazard ratio: 0.942; 95% confidence interval: 0.742, 1.195). These analyses showed that the efficacy of adjuvant abemaciclib was not compromised by protocol mandated dose reductions for patients with node positive, hormone receptor positive, human epidermal growth factor 2-negative, high-risk early breast cancer.
    Language English
    Publishing date 2024-04-26
    Publishing country United States
    Document type Journal Article
    ISSN 2374-4677
    ISSN 2374-4677
    DOI 10.1038/s41523-024-00639-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Challenging Cosmetic Innovation: The Skin Microbiota and Probiotics Protect the Skin from UV-Induced Damage

    Souak, Djouhar / Barreau, Magalie / Courtois, Aurélie / André, Valérie / Duclairoir Poc, Cécile / Feuilloley, Marc G. J / Gault, Manon

    Microorganisms. 2021 Apr. 27, v. 9, no. 5

    2021  

    Abstract: Many studies performed in the last decade have focused on the cutaneous microbiota. It has been shown that this microbiota plays a key role in skin homeostasis. Considered as “a second barrier” to the environment, it is very important to know how it ... ...

    Abstract Many studies performed in the last decade have focused on the cutaneous microbiota. It has been shown that this microbiota plays a key role in skin homeostasis. Considered as “a second barrier” to the environment, it is very important to know how it reacts to exogenous aggressions. The cosmetics industry has a started to use this microbiota as a source of natural ingredients, particularly ones that confer photoprotection against ultraviolet (UV) rays. Interestingly, it has been demonstrated that bacterial molecules can block UV rays or reverse their harmful effects. Oral probiotics containing living microorganisms have also shown promising results in restoring skin homeostasis and reversing the negative effects of UV rays. Microbial-based active sunscreen compounds have huge potential for use as next-generation photoprotection products.
    Keywords homeostasis ; industry ; probiotics ; radiation resistance ; sunscreens
    Language English
    Dates of publication 2021-0427
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    Note NAL-AP-2-clean
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms9050936
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Challenging Cosmetic Innovation: The Skin Microbiota and Probiotics Protect the Skin from UV-Induced Damage.

    Souak, Djouhar / Barreau, Magalie / Courtois, Aurélie / André, Valérie / Duclairoir Poc, Cécile / Feuilloley, Marc G J / Gault, Manon

    Microorganisms

    2021  Volume 9, Issue 5

    Abstract: Many studies performed in the last decade have focused on the cutaneous microbiota. It has been shown that this microbiota plays a key role in skin homeostasis. Considered as "a second barrier" to the environment, it is very important to know how it ... ...

    Abstract Many studies performed in the last decade have focused on the cutaneous microbiota. It has been shown that this microbiota plays a key role in skin homeostasis. Considered as "a second barrier" to the environment, it is very important to know how it reacts to exogenous aggressions. The cosmetics industry has a started to use this microbiota as a source of natural ingredients, particularly ones that confer photoprotection against ultraviolet (UV) rays. Interestingly, it has been demonstrated that bacterial molecules can block UV rays or reverse their harmful effects. Oral probiotics containing living microorganisms have also shown promising results in restoring skin homeostasis and reversing the negative effects of UV rays. Microbial-based active sunscreen compounds have huge potential for use as next-generation photoprotection products.
    Language English
    Publishing date 2021-04-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms9050936
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Microfluidic arrays of dermal spheroids: a screening platform for active ingredients of skincare products.

    Chen, Zhengkun / Kheiri, Sina / Gevorkian, Albert / Young, Edmond W K / Andre, Valerie / Deisenroth, Ted / Kumacheva, Eugenia

    Lab on a chip

    2021  Volume 21, Issue 20, Page(s) 3952–3962

    Abstract: Organotypic micrometre-size 3D aggregates of skin cells (multicellular spheroids) have emerged as a ... ...

    Abstract Organotypic micrometre-size 3D aggregates of skin cells (multicellular spheroids) have emerged as a promising
    MeSH term(s) Animals ; Cell Culture Techniques ; Hydrogels ; Microfluidics ; Spheroids, Cellular
    Chemical Substances Hydrogels
    Language English
    Publishing date 2021-10-12
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2056646-3
    ISSN 1473-0189 ; 1473-0197
    ISSN (online) 1473-0189
    ISSN 1473-0197
    DOI 10.1039/d1lc00619c
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

    Rastogi, Priya / O'Shaughnessy, Joyce / Martin, Miguel / Boyle, Frances / Cortes, Javier / Rugo, Hope S / Goetz, Matthew P / Hamilton, Erika P / Huang, Chiun-Sheng / Senkus, Elzbieta / Tryakin, Alexey / Cicin, Irfan / Testa, Laura / Neven, Patrick / Huober, Jens / Shao, Zhimin / Wei, Ran / André, Valérie / Munoz, Maria /
    San Antonio, Belen / Shahir, Ashwin / Harbeck, Nadia / Johnston, Stephen

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2024  Volume 42, Issue 9, Page(s) 987–993

    Abstract: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial ... ...

    Abstract Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Neoplasm Recurrence, Local ; Adjuvants, Immunologic ; Receptor, ErbB-2 ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Aminopyridines ; Benzimidazoles
    Chemical Substances abemaciclib (60UAB198HK) ; ERBB2 protein, human (EC 2.7.10.1) ; Adjuvants, Immunologic ; Receptor, ErbB-2 (EC 2.7.10.1) ; Aminopyridines ; Benzimidazoles
    Language English
    Publishing date 2024-01-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.01994
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors.

    Ueno, Hideki / Kondo, Shunsuke / Yoshikawa, Shusuke / Inoue, Koichi / Andre, Valérie / Tajimi, Masaomi / Murakami, Haruyasu

    Investigational new drugs

    2018  Volume 36, Issue 4, Page(s) 647–656

    Abstract: Background This phase I dose-escalation study investigated the safety of the Smoothened inhibitor taladegib in Japanese patients with advanced solid tumors. Methods Patients received taladegib orally once daily for 28-day cycles, using a 3 + 3 dose- ... ...

    Abstract Background This phase I dose-escalation study investigated the safety of the Smoothened inhibitor taladegib in Japanese patients with advanced solid tumors. Methods Patients received taladegib orally once daily for 28-day cycles, using a 3 + 3 dose-escalation method. The primary objective was the safety and tolerability of taladegib at doses up to the global recommended dose (400 mg). Secondary objectives included pharmacokinetics, changes in skin glioma-associated oncogene homolog 1 (Gli1) transcript levels, and antitumor activity. Results Nineteen patients received treatment (100 mg: 3; 200 mg: 3; 400 mg: 13). No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2). The most commonly reported treatment-related adverse events were dysgeusia (13/19, 68.4%), decreased appetite (12/19, 63.2%), nausea (9/19, 47.4%), fatigue (9/19, 47.4%), and vomiting (6/19, 31.6%). The pharmacokinetic profile suggested that exposure to taladegib was higher in Japanese than non-Japanese patients, possibly related to differences in body weight and/or drug formulation. At all dose levels, a high level of inhibition of skin Gli1 transcript levels was observed after 15 and 30 days of exposure to taladegib. Partial response was achieved by 1 patient (basal cell carcinoma of the skin) and stable disease by 4 patients. Conclusions Taladegib doses of 100 mg and 200 mg, but not the global recommended dose of 400 mg, were well tolerated in this population of Japanese patients with advanced solid tumors.
    MeSH term(s) Adult ; Aged ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/therapeutic use ; Asian Continental Ancestry Group ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/drug therapy ; Smoothened Receptor/antagonists & inhibitors
    Chemical Substances Antineoplastic Agents ; Smoothened Receptor
    Language English
    Publishing date 2018-02-17
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604895-x
    ISSN 1573-0646 ; 0167-6997
    ISSN (online) 1573-0646
    ISSN 0167-6997
    DOI 10.1007/s10637-017-0544-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1823: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top